Chicago-Patients with carcinoma in situ or recurrent Ta, Tis, or T1 bladder cancer are at increased risk of dying of the disease within 5 years unless they achieve a complete response with bacille Calmette-Guérin therapy, say researchers from the Southwest Oncology Group. ...